Breast cancer has a long natural history. Established and emerging biologic markers address overall risk but not necessarily timing of recurrence. 346 adjuvant na <ve breast cancer cases from Guy's Hospital with 23 years minimum follow-up and archival blocks were recut and reassessed for hormone-receptors (HR), HER2-receptor and grade. Disease-specific survival (DSS) was analyzed by recursive partitioning. To validate insights from this analysis, gene-signatures (proliferative and HR-negative) were evaluated for their ability to predict early versus late metastatic risk in 683 node-negative, adjuvant na <ve breast cancers annotated with expression microarray data. Risk partitioning showed that adjuvant na <ve node-negative outcome ...
Background Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer h...
Purpose: To identify the individual genes or gene modules that lead to the OncoptypeDx 21-gene recur...
Abstract Introduction Outcome predictors in use today are prognostic only for hormone receptor-posit...
The 70-gene signature (MammaPrint (TM)) has been developed to predict the risk of distant metastases...
Background: Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer ...
BackgroundGiven the large number of genes purported to be prognostic for breast cancer, it would be ...
Abstract Introduction Various multigene predictors of breast cancer clinical outcome have been comme...
IntroductionBreast cancer risk of recurrence is known to span 20 years, yet existing prognostic sign...
The molecular profiling of breast tumors using the powerful microarray technology has uncovered the ...
The rates and routes of lethal systemic spread in breast cancer are poorly understood owing to a lac...
Introduction: Prognostic gene expression signatures can be used in combination with classical clinic...
Determining which patients with early-stage breast cancer should receive chemotherapy is an importan...
Breast cancer (BC) is a heterogeneous disease consisting of distinct subtypes that vary in prognosis...
Introduction: Prognostic gene expression signatures can be used in combination with classical clinic...
Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending...
Background Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer h...
Purpose: To identify the individual genes or gene modules that lead to the OncoptypeDx 21-gene recur...
Abstract Introduction Outcome predictors in use today are prognostic only for hormone receptor-posit...
The 70-gene signature (MammaPrint (TM)) has been developed to predict the risk of distant metastases...
Background: Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer ...
BackgroundGiven the large number of genes purported to be prognostic for breast cancer, it would be ...
Abstract Introduction Various multigene predictors of breast cancer clinical outcome have been comme...
IntroductionBreast cancer risk of recurrence is known to span 20 years, yet existing prognostic sign...
The molecular profiling of breast tumors using the powerful microarray technology has uncovered the ...
The rates and routes of lethal systemic spread in breast cancer are poorly understood owing to a lac...
Introduction: Prognostic gene expression signatures can be used in combination with classical clinic...
Determining which patients with early-stage breast cancer should receive chemotherapy is an importan...
Breast cancer (BC) is a heterogeneous disease consisting of distinct subtypes that vary in prognosis...
Introduction: Prognostic gene expression signatures can be used in combination with classical clinic...
Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending...
Background Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer h...
Purpose: To identify the individual genes or gene modules that lead to the OncoptypeDx 21-gene recur...
Abstract Introduction Outcome predictors in use today are prognostic only for hormone receptor-posit...